Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P.R. China.
Department of Oncology, Hubei Cancer Hospital, Affiliated Hubei Cancer Hospital of Huazhong University of Science and Technology, Wuhan, 430079, P.R. China.
BMC Cancer. 2021 Jan 5;21(1):18. doi: 10.1186/s12885-020-07726-z.
Clear cell renal cell carcinoma is susceptible to ferroptosis, and immunotherapy is recently recommended as a priority for the initial treatment of metastatic clear cell renal carcinoma. Increased ferroptosis and immune activation can synergistically reinforce each other in killing cancer cells. NCOA4 depletion can eliminate iron accumulation and thus weaken ferroptosis. Here, we aim to identify and validate the association between NCOA4 expression, clinicopathologic characteristics, and overall survival in ccRCC by using The Cancer Genome Atlas and Gene Expression Omnibus databases. We further analyze the interacted proteins of NCOA4 and infiltrated immune cells via TIMER and GEPIA databases.
NCOA4 expression in clear cell renal carcinoma (ccRCC) tissues and normal adjacent tissues in The Cancer Genome Atlas (TCGA) data were primarily screened, and further validated in another independent cohort from the gene expression omnibus (GEO) database and human protein atlas. The relationships of NCOA4 expression and clinicopathologic parameters and overall survival (OS) were assessed using multivariate methods and Kaplan-Meier survival curves. And the proteins network with which NCOA4 interacted were also built using the online STRING website. Meanwhile, we use TIMER and GEPIA databases to investigate the relationships between NCOA4 expression and infiltrated immune cells and their corresponding gene marker sets.
Contrast to normal tissue, NCOA4 expression was lower in ccRCC tumor tissue(p < 0.05). Lower NCOA4 expression was closely associated with high-grade malignancy and advanced TNM stage. Univariate and multivariate analysis indicated the overall survival of ccRCC cases with low NCOA4 level is shorter than those of patients with high NCOA4 expression (p < 0.05). FTL and FTH1 were the important proteins interacting with NCOA4. ccRCC with NCOA4 deficiency presented the paucity of infiltrated immune cells and their matching marker sets, including CD8+ T cells.
Deficient NCOA4 expression was related to disease progression and poor prognosis, as well as impaired infiltration of immune cells in ccRCC.
透明细胞肾细胞癌易发生铁死亡,最近免疫疗法被推荐作为转移性透明细胞肾细胞癌初始治疗的首选方法。增加铁死亡和免疫激活可以协同作用,共同杀死癌细胞。NCOA4 耗竭可以消除铁积累,从而减弱铁死亡。在这里,我们旨在通过使用癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)数据库来鉴定和验证 NCOA4 表达与 ccRCC 的临床病理特征和总生存期之间的关联。我们还通过 TIMER 和 GEPIA 数据库分析了 NCOA4 与浸润免疫细胞的相互作用蛋白。
首先筛选 TCGA 数据中透明细胞肾细胞癌(ccRCC)组织和正常相邻组织中的 NCOA4 表达,并在 GEO 数据库和人类蛋白质图谱中的另一个独立队列中进一步验证。使用多变量方法和 Kaplan-Meier 生存曲线评估 NCOA4 表达与临床病理参数和总生存期(OS)的关系。并使用在线 STRING 网站构建与 NCOA4 相互作用的蛋白质网络。同时,我们使用 TIMER 和 GEPIA 数据库来研究 NCOA4 表达与浸润免疫细胞及其相应基因标记集之间的关系。
与正常组织相比,ccRCC 肿瘤组织中 NCOA4 表达降低(p<0.05)。较低的 NCOA4 表达与高级别恶性肿瘤和晚期 TNM 分期密切相关。单因素和多因素分析表明,NCOA4 低表达的 ccRCC 病例的总生存期短于 NCOA4 高表达的患者(p<0.05)。FTL 和 FTH1 是与 NCOA4 相互作用的重要蛋白。NCOA4 缺陷的 ccRCC 表现为浸润免疫细胞及其匹配标记集(包括 CD8+T 细胞)的缺乏。
NCOA4 表达缺失与 ccRCC 疾病进展和预后不良以及浸润免疫细胞受损有关。